Jun 2026 (Q2 FY26) — Aug 10, 2026
BridgeBio Pharma, Inc. Q2 FY26 — Attruby Growth and Pipeline Advancement
Read the full callBridgeBio Pharma (BBIO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
BridgeBio Pharma earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 244 | +120.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -43.9 | +77.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. |
Guidance
What management said, and what became of it
8 of 9 judged targets kept · 12 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Infigratinib PROPEL 3 data presentation | presenting the full PROPEL 3 data set | Mar 2026 | we presented our Phase III PROPEL 3 results at the International Conference on Children's Bone Health (sic) [ International Congress of Children s Bone Health ] on June 30 and simultaneously published them in The New England Journal of Medicine | Achieved |
| Gondola Bio EPP program Phase III data | Phase III data | Mar 2025 | Our program in EPP announced positive Phase IIa data in June. And following a productive EOP2 meeting with the agency, we will be initiating a Phase IIb/III study in Q3 of this year. | Delayed |
| Attruby Afib data presentation | present the first results at ESC | Mar 2025 | Ghosted |
1 of BridgeBio Pharma, Inc.'s 21 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 18 more targets are in the full ledger.
Claimed
- Attruby net product revenue grew to $222.4 million, marking over $35 million sequential sales increase.
- Attruby demonstrated continued commercial momentum, being the fastest-growing brand in its space at 23% this quarter.
- All three late-stage pipeline programs (LGMD2I, ADH1, achondroplasia) moved into regulatory review, with LGMD2I and ADH1 receiving priority review and the first PDUFA date set for November 27.
- Completed a $1 billion preferred equity financing on July 1, 2026, increasing cash balance to approximately $1.7 billion.
- Observed the first evidence of direct kidney protection for Attruby in ATTR-CM, with a hazard ratio of 0.42 for all-cause mortality or cardiovascular-related hospitalization in patients with acute eGFR dips.
Qualified
- The second-line/switch segment for Attruby is settling into a lower, more normalized steady state after forced VYNDAQEL switching largely worked through.
- The CARDIO-TTRansform study for eplontersen in ATTR cardiomyopathy did not meet its primary efficacy endpoint, suggesting no benefit from combination therapy.
- License and services revenue decreased to $5.8 million from $37.4 million in Q2 FY25, primarily due to a one-time $30 million regulatory milestone in the prior year.
Price
$66.39 −1.10% · −$0.74
Performance +17.2% 1Y
1Y: $56.63 on 15 Oct 2025 → $66.39. High $90.17 (9 Jul 2026), low $53.24 (22 Oct 2025).
- Previous close
- $67.13
- 52-week range
- $53.24 – $90.17
- One year
- +20.64%
Overview
- Symbol
- BBIO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
8 of 9 judged targets kept · 12 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Infigratinib PROPEL 3 data presentation | presenting the full PROPEL 3 data set | Mar 2026 | we presented our Phase III PROPEL 3 results at the International Conference on Children's Bone Health (sic) [ International Congress of Children s Bone Health ] on June 30 and simultaneously published them in The New England Journal of Medicine | Achieved |
| Gondola Bio EPP program Phase III data | Phase III data | Mar 2025 | Our program in EPP announced positive Phase IIa data in June. And following a productive EOP2 meeting with the agency, we will be initiating a Phase IIb/III study in Q3 of this year. | Delayed |
| Attruby Afib data presentation | present the first results at ESC | Mar 2025 | Ghosted |
Claimed
- Attruby net product revenue grew to $222.4 million, marking over $35 million sequential sales increase.
- Attruby demonstrated continued commercial momentum, being the fastest-growing brand in its space at 23% this quarter.
- All three late-stage pipeline programs (LGMD2I, ADH1, achondroplasia) moved into regulatory review, with LGMD2I and ADH1 receiving priority review and the first PDUFA date set for November 27.
- Completed a $1 billion preferred equity financing on July 1, 2026, increasing cash balance to approximately $1.7 billion.
- Observed the first evidence of direct kidney protection for Attruby in ATTR-CM, with a hazard ratio of 0.42 for all-cause mortality or cardiovascular-related hospitalization in patients with acute eGFR dips.
Qualified
- The second-line/switch segment for Attruby is settling into a lower, more normalized steady state after forced VYNDAQEL switching largely worked through.
- The CARDIO-TTRansform study for eplontersen in ATTR cardiomyopathy did not meet its primary efficacy endpoint, suggesting no benefit from combination therapy.
- License and services revenue decreased to $5.8 million from $37.4 million in Q2 FY25, primarily due to a one-time $30 million regulatory milestone in the prior year.
The full ledger
Open BridgeBio Pharma, Inc.’s full ledger
A free account opens 5 company ledgers a month. All 21 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
BridgeBio Pharma Q1 FY26 — Strong Attruby Growth and Share Repurchase Program
Read the full callDec 2025 (Q4 FY25) — Feb 24, 2026
BridgeBio Q4 FY25 — Transformative Inflection Point with Multiple Late-Stage Readouts and Strong Attruby Growth
Read the full callEvery analysed call
BridgeBio Pharma earnings calls (BBIO)
Financials
What the filings say
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 6 | 117 | 111 | 121 | 154 | 195 | 244 |
| Expenses | 194 | 232 | 221 | 245 | 266 | 294 | 300 | 351 |
| Operating profit | -192 | -226 | -104 | -134 | -145 | -140 | -106 | -107 |
| Operating margin | −7018.7% | −3842.7% | −89.5% | −121.5% | −120.3% | −90.5% | −54.5% | −43.9% |
| Other income | 27 | -40 | -65 | -47 | -41 | -55 | -61 | -49 |
| Interest | 23 | 30 | 18 | 12 | 12 | 12 | 13 | 13 |
| Profit before tax | -164 | — | — | -182 | -186 | -195 | — | -156 |
| Tax rate | 0.0% | — | — | −1.2% | 0.8% | 0.1% | — | 0.0% |
| EPS ($ per share) | -0.86 | — | -0.88 | -0.95 | -0.95 | — | -0.84 | -0.78 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -179 | -440 | -889 | -1,437 | -1,918 | -2,561 | -3,096 | -3,821 |
| Total liabilities | 88 | 156 | 596 | 1,878 | 1,868 | 1,889 | 2,377 | 3,013 |
| Fixed assets | 2 | 6 | 20 | 30 | 15 | 12 | 7 | 5 |
| Investments | — | 182 | 251 | 394 | 52 | 0 | 0 | — |
| Total assets | 465 | 632 | 704 | 1,013 | 623 | 546 | 919 | 936 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -137 | -254 | -400 | -498 | -419 | -528 | -521 | -446 |
| Cash from investing | -21 | -217 | -53 | -201 | 453 | 54 | 61 | -24 |
| Cash from financing | 502 | 399 | 447 | 736 | -13 | 452 | 748 | 359 |
| Net cash flow | 344 | -72 | -6 | 38 | 21 | -22 | 289 | -111 |
| Capital expenditure | -2 | -3 | -8 | -13 | -5 | -1 | -1 | -1 |
| Free cash flow | -139 | -256 | -407 | -511 | -424 | -529 | -522 | -447 |
BBIO revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|
| Reportable | — | — | — | — | 100% | 100% | 100% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
221 filings between Oct 27, 2025 and Sep 17, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$118.36M
159 sales by 10 insiders
96% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 14
- Award — granted as compensation
- 32
- Option exercise — converted options into shares
- 16
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Kumar Neil | — | $57.15M | Sep 17, 2026 |
| Cook Jennifer E. | — | $21.92M | Jul 9, 2026 |
| MCCORMICK FRANK | — | $13.31M | Oct 29, 2025 |
| Lo Andrew | — | $6.32M | Nov 18, 2025 |
| Ellis Andrea | — | $5.65M | Jul 9, 2026 |
| Valantine Hannah | — | $4.37M | Jun 23, 2026 |
| DANIELS RONALD J | — | $3.89M | Nov 6, 2025 |
| Trimarchi Thomas | — | $3.03M | May 18, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 17, 2026 | Kumar Neil Chief Executive Officer | Sale 10b5-1 plan | 8,721 | $601.9K |
| Sep 17, 2026 | Kumar Neil Chief Executive Officer | Sale 10b5-1 plan | 1,279 | $89.0K |
| Aug 19, 2026 | Kumar Neil Chief Executive Officer | Sale 10b5-1 plan | 8,100 | $679.3K |
| Aug 19, 2026 | Kumar Neil Chief Executive Officer | Sale 10b5-1 plan | 100 | $8.6K |
| Aug 19, 2026 | Kumar Neil Chief Executive Officer | Sale 10b5-1 plan | 1,800 | $152.4K |
| Aug 18, 2026 | Kumar Neil Chief Executive Officer | Sale 10b5-1 plan | 1,900 | $154.2K |
| Aug 18, 2026 | Kumar Neil Chief Executive Officer | Sale 10b5-1 plan | 1,199 | $100.4K |
| Aug 18, 2026 | Kumar Neil Chief Executive Officer | Sale 10b5-1 plan | 14,602 | $1.21M |
| Aug 18, 2026 | Kumar Neil Chief Executive Officer | Sale 10b5-1 plan | 17,279 | $1.42M |
| Aug 16, 2026 | Kumar Neil Chief Executive Officer | Option exercise | 6,520 | — |
| Aug 16, 2026 | Kumar Neil Chief Executive Officer | Option exercise | 19,599 | — |
| Aug 16, 2026 | Kumar Neil Chief Executive Officer | Tax withheld | 36,237 | $2.89M |
| Aug 16, 2026 | Apuli Maricel Chief Accounting Officer | Tax withheld | 4,714 | $376.5K |
| Aug 16, 2026 | Kumar Neil Chief Executive Officer | Option exercise | 33,544 | — |
| Aug 16, 2026 | Trimarchi Thomas President and CFO | Tax withheld | 22,781 | $1.82M |
| Aug 16, 2026 | Kumar Neil Chief Executive Officer | Option exercise | 11,554 | — |
| Jul 30, 2026 | Apuli Maricel Chief Accounting Officer | Sale 10b5-1 plan | 2,000 | $160.1K |
| Jul 9, 2026 | Ellis Andrea Director | Option exercise 10b5-1 plan | 17,167 | $287.5K |
| Jul 9, 2026 | Cook Jennifer E. Director | Option exercise 10b5-1 plan | 112,422 | $3.26M |
| Jul 9, 2026 | Cook Jennifer E. Director | Sale 10b5-1 plan | 36,167 | $3.04M |
| Jul 9, 2026 | Cook Jennifer E. Director | Sale 10b5-1 plan | 112,422 | $10.12M |
| Jul 9, 2026 | Ellis Andrea Director | Sale 10b5-1 plan | 17,167 | $1.44M |
| Jul 9, 2026 | Cook Jennifer E. Director | Option exercise 10b5-1 plan | 19,000 | $160.6K |
| Jul 9, 2026 | Cook Jennifer E. Director | Option exercise 10b5-1 plan | 17,167 | $287.5K |
| Jun 24, 2026 | Cook Jennifer E. Director | Sale 10b5-1 plan | 37,167 | $2.60M |
| Jun 24, 2026 | Cook Jennifer E. Director | Option exercise 10b5-1 plan | 17,167 | $287.5K |
| Jun 24, 2026 | Cook Jennifer E. Director | Option exercise 10b5-1 plan | 20,000 | $169.0K |
| Jun 23, 2026 | Cook Jennifer E. Director | Sale 10b5-1 plan | 2,196 | $150.6K |
| Jun 23, 2026 | Valantine Hannah Director | Sale 10b5-1 plan | 2,196 | $150.6K |
| Jun 22, 2026 | HOMCY CHARLES J Director | Award | 3,990 | $0 |
| Jun 22, 2026 | AGUIAR ERIC Director | Award | 3,990 | $0 |
| Jun 22, 2026 | DANIELS RONALD J Director | Award | 3,990 | $0 |
| Jun 22, 2026 | Ellis Andrea Director | Award | 3,990 | $0 |
| Jun 22, 2026 | Hassan Fred Director | Award | 3,990 | $0 |
| Jun 22, 2026 | MOMTAZEE JAMES C Director | Award | 3,990 | $0 |
| Jun 22, 2026 | Dachille Douglas A. Director | Award | 3,990 | $0 |
| Jun 22, 2026 | MCCORMICK FRANK Director | Award | 3,990 | $0 |
| Jun 22, 2026 | Satvat Ali J. Director | Award | 3,990 | $0 |
| Jun 22, 2026 | Lo Andrew Director | Award | 3,990 | $0 |
| Jun 22, 2026 | Cook Jennifer E. Director | Award 10b5-1 plan | 3,990 | $0 |
| Jun 22, 2026 | Valantine Hannah Director | Sale 10b5-1 plan | 2,808 | $190.9K |
| Jun 22, 2026 | Valantine Hannah Director | Option exercise 10b5-1 plan | 2,808 | $117.2K |
| Jun 22, 2026 | Valantine Hannah Director | Award 10b5-1 plan | 3,990 | $0 |
| Jun 20, 2026 | HOMCY CHARLES J Director | Tax withheld | 788 | $52.2K |
| Jun 15, 2026 | Cook Jennifer E. Director | Sale 10b5-1 plan | 1,503 | $100.9K |
| Jun 15, 2026 | Cook Jennifer E. Director | Sale 10b5-1 plan | 88,737 | $5.91M |
| Jun 15, 2026 | Cook Jennifer E. Director | Option exercise 10b5-1 plan | 17,167 | $287.5K |
| Jun 15, 2026 | Cook Jennifer E. Director | Option exercise 10b5-1 plan | 65,921 | $557.0K |
| Jun 5, 2026 | Kumar Neil Chief Executive Officer | Sale 10b5-1 plan | 7,147 | $480.3K |
| Jun 5, 2026 | Kumar Neil Chief Executive Officer | Sale 10b5-1 plan | 8,437 | $572.7K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for BridgeBio Pharma, Inc.
Free account. Everything above stays public.
Write why you follow BridgeBio Pharma, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading